TCR V β 5 Antibody (MEM-262): sc-51704

TCR V β 5 Antibody (MEM-262) is a mouse monoclonal IgG2a antibody that detects T cell receptor V β 5 (TCR V β 5) in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and flow cytometry (FCM). TCR V β 5 plays a crucial role in the immune response by recognizing specific antigens presented by major histocompatibility complex (MHC) molecules, which is essential for the activation and proliferation of T cells. TCR V β 5 is primarily located on the surface of T cells, where TCR V β 5 forms part of the T cell receptor complex, allowing T cells to distinguish between self and non-self antigens. The ability of TCR V β 5 to recognize a diverse array of antigens is vital for the adaptive immune system, as TCR V β 5 enables the body to mount effective responses against various pathogens. Additionally, TCR V β 5 chain is involved in the somatic recombination process that generates the diverse T cell receptor repertoire, ensuring that T cells can respond to a wide range of antigens. Understanding the function and significance of TCR V β 5 is important for research into T cell development and the mechanisms underlying immune responses, as well as for potential therapeutic applications in immunology and oncology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TCR V β 5 Antibody (MEM-262) References:

1. Chronic modulation of the TCR repertoire in the lymphoid periphery.  |  Blish, CA., et al. 1999. J Immunol. 162: 3131-40. PMID: 10092762
2. HLA-DQ beta chain can present mouse endogenous provirus MTV-9 product and clonally delete Tcr V beta 5+ and V beta 11+ T cells in transgenic mice.  |  Zhou, P., et al. 1992. Immunogenetics. 35: 219-23. PMID: 1311702
3. Evidence for a role for T cell receptors (TCR) in the effector phase of acute bone marrow graft rejection. TCR V beta 5 transgenic mice lack effector cells able to cause graft rejection.  |  Kikly, K. and Dennert, G. 1992. J Immunol. 149: 3489-94. PMID: 1431119
4. T-cell receptor variable (V) gene usage by lymphoid populations in T-cell lymphoma.  |  Smith, JL., et al. 1992. J Pathol. 166: 109-12. PMID: 1560311
5. Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides.  |  Bourdette, DN., et al. 1994. J Immunol. 152: 2510-9. PMID: 7510746
6. Expanded TcR V beta 5.1 family in a diffuse high-grade B cell immunoblastic lymphoma.  |  Hodges, E., et al. 1995. Leukemia. 9: 1108-12. PMID: 7596179
7. T cell receptor V beta repertoire in mice lacking endogenous mouse mammary tumor provirus.  |  Braun, MY., et al. 1995. Eur J Immunol. 25: 857-62. PMID: 7705418
8. BUB/BnJ (H-2q) is a TCR deletion mutant mouse strain (TCR V beta a, KJ16-) that is susceptible to type II collagen-induced arthritis.  |  Ortman, RA., et al. 1994. J Immunol. 152: 4175-82. PMID: 8144978
9. CD8high+ (CD57+) T cells in patients with rheumatoid arthritis.  |  Wang, EC., et al. 1997. Arthritis Rheum. 40: 237-48. PMID: 9041935
10. T cell receptor V beta 5 and V beta 17 clonal diversity in cerebrospinal fluid and peripheral blood lymphocytes of multiple sclerosis patients.  |  Lozeron, P., et al. 1998. Mult Scler. 4: 154-61. PMID: 9762666

The preferred TCR β antibody is TCR β Antibody (G-11): sc-5277.